tldrdailynews.com logo

Intellia Temporarily Pauses Late-Stage Gene-Editing Trials Amid Safety Concerns

1 min read
Source: Intellia Therapeutics
TL;DR

Intellia Therapeutics has temporarily paused its Phase 3 clinical trials of Nex-z for transthyretin amyloidosis after a patient experienced severe liver-related side effects, with plans to investigate and consult with regulators before resuming the trials.

Topics:businesshealthcare#clinical-trials#gene-editing#healthcare#intellia-therapeutics#magnitude#nex-z
Share this article
  1. Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)  Intellia Therapeutics
  2. Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern  statnews.com
  3. Intellia pauses trials after serious liver event in gene therapy patient  Investing.com Nigeria
  4. Intellia Temporarily Pauses Dosing For MAGNITUDE And MAGNITUDE-2 Phase 3 Clinical Trials Of Nex-z  Nasdaq
  5. Intellia pauses late-stage trials of gene-editing treatment after serious liver event  TradingView

Want the full story? Read the original reporting

Read on Intellia Therapeutics